Beam Therapeutics Inc. - Understand $beam stock

$BEAM Market Cap: $2.155 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$349.6M

TTM

Gross Margin

Net Earnings

-$143.6M

TTM

Current Assets

$945.5M

Q3 2024

Current Liabilities

$166.2M

Q3 2024

Current Ratio

568.76%

Q3 2024

Total Assets

$1.171B

Q3 2024

Total Liabilities

$380.1M

Q3 2024

Book Value

$791.3M

Q3 2024

Cash

$230.2M

Q3 2024

P/E

-15.01

Nov 29, 2024 EST

Free Cash Flow

-$145.4M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$377.7M	$60.92M	$51.84M	$24.00K	$18.00K	$0.00	$0.00
YoY Change	520.01%	17.51%	215916.67%	33.33%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$377.7M	$60.92M	$51.84M	$24.00K	$18.00K	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$116.8M	$87.81M	$57.22M	$29.61M	$20.55M	$11.87M	$2.020M
YoY Change	33.04%	53.45%	93.25%	44.09%	73.13%	487.62%
% of Gross Profit
Research & Development	$437.4M	$311.6M	$387.1M	$103.2M	$54.62M	$33.87M	$5.860M
YoY Change	40.37%	-19.5%	275.16%	88.91%	61.26%	477.99%
% of Gross Profit
Depreciation & Amortization	$20.01M	$14.15M	$7.451M	$4.735M	$3.503M	$650.0K	$10.00K
YoY Change	41.46%	89.87%	57.36%	35.17%	438.92%	6400.0%
% of Gross Profit
Operating Expenses	$554.2M	$399.4M	$444.3M	$132.8M	$75.17M	$45.74M	$7.880M
YoY Change	38.76%	-10.11%	234.61%	76.64%	64.35%	480.46%
Operating Profit	-$176.5M	-$338.5M	-$392.5M	-$132.8M	-$75.15M
YoY Change	-47.86%	-13.76%	195.62%	76.65%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$35.58M	$59.40M	-$1.009M	-$61.83M	-$3.100M	-$11.46M	-$500.0K
YoY Change	-40.09%	-5986.72%	-98.37%	1894.52%	-72.95%	2192.0%
% of Operating Profit
Other Income/Expense, Net	$45.32M	$78.30M	$21.83M	-$61.83M	-$3.172M	-$59.54M	$380.0K
YoY Change	-42.12%	258.73%	-135.3%	1849.31%	-94.67%	-15768.42%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$131.2M	-$260.2M	-$370.6M	-$194.6M	-$78.33M	-$116.7M	-$8.000M
YoY Change	-49.59%	-29.8%	90.47%	148.42%	-32.9%	1359.25%
Income Tax	$1.366M	$3.400M	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$132.5M	-$289.1M	-$370.6M	-$194.6M	-$78.33M	-$115.3M	-$8.000M
YoY Change	-54.16%	-22.0%	90.47%	148.44%	-32.04%	1340.75%
Net Earnings / Revenue	-35.09%	-474.54%	-714.91%	-810800.0%	-435144.44%
Basic Earnings Per Share	-$1.72	-$4.13	-$5.77	-$4.19	-$14.05
Diluted Earnings Per Share	-$1.72	-$4.13	-$5.77	-$4.19	-$14.05	-$2.543M	-$176.5K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$1.190B	$1.078B	$965.6M	$299.7M	$91.80M	$146.4M	$1.900M
YoY Change	10.36%	11.65%	222.2%	226.47%	-37.3%	7605.26%
Cash & Equivalents	$435.9M	$232.8M	$560.0M	$162.2M	$37.20M	$146.4M	$1.900M
Short-Term Investments	$754.0M	$845.4M	$405.7M	$137.5M	$54.60M
Other Short-Term Assets	$21.17M	$14.76M	$7.360M	$8.700M	$2.700M	$1.800M	$100.0K
YoY Change	43.39%	100.57%	-15.4%	222.22%	50.0%	1700.0%
Inventory
Prepaid Expenses
Receivables		$0.00	$300.0M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$1.211B	$1.093B	$1.273B	$308.3M	$94.50M	$148.3M	$2.000M
YoY Change	10.81%	-14.15%	312.91%	226.24%	-36.28%	7315.0%
Property, Plant & Equipment	$237.8M	$234.1M	$187.0M	$125.4M	$43.20M	$16.90M	$300.0K
YoY Change	1.57%	25.22%	49.1%	190.28%	155.62%	5533.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.87M	$14.69M	$14.47M	$18.00M	$18.30M	$1.800M	$0.00
YoY Change	-26.01%	1.49%	-19.61%	-1.64%	916.67%
Total Long-Term Assets	$248.7M	$248.8M	$201.4M	$143.4M	$61.60M	$18.70M	$400.0K
YoY Change	-0.06%	23.52%	40.48%	132.79%	229.41%	4575.0%
Total Assets	$1.460B	$1.342B	$1.474B	$451.7M	$156.1M	$167.0M	$2.400M
YoY Change
Accounts Payable	$1.617M	$9.029M	$7.474M	$6.300M	$7.800M	$7.400M	$700.0K
YoY Change	-82.09%	20.81%	18.63%	-19.23%	5.41%	957.14%
Accrued Expenses	$124.0M	$58.44M	$75.20M	$22.70M	$12.20M	$1.700M	$100.0K
YoY Change	112.12%	-22.29%	231.3%	86.07%	617.65%	1600.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$484.0K	$1.853M	$2.287M	$2.100M	$1.300M	$13.80M	$0.00
YoY Change	-73.88%	-18.98%	8.9%	61.54%	-90.58%
Total Short-Term Liabilities	$205.6M	$223.6M	$213.4M	$102.3M	$29.10M	$25.60M	$6.600M
YoY Change	-8.06%	4.76%	108.64%	251.55%	13.67%	287.88%
Long-Term Debt	$0.00	$1.154M	$3.007M	$5.300M	$4.400M	$0.00	$0.00
YoY Change	-100.0%	-61.62%	-43.26%	20.45%
Other Long-Term Liabilities	$272.8M	$383.5M	$431.3M	$98.50M	$21.60M	$7.400M	$0.00
YoY Change	-28.86%	-11.08%	337.84%	356.02%	191.89%
Total Long-Term Liabilities	$272.8M	$384.6M	$434.3M	$103.8M	$26.00M	$7.400M	$0.00
YoY Change	-29.07%	-11.43%	318.38%	299.23%	251.35%
Total Liabilities	$478.4M	$608.2M	$647.7M	$206.1M	$55.20M	$33.00M	$6.600M
YoY Change	-21.35%	-6.09%	214.27%	273.37%	67.27%	400.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	77.15M	70.02M	64.23M	46.73M	6.480M
Diluted Shares Outstanding	77.15M	70.02M	64.23M	46.73M	6.480M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.1546 Billion

About Beam Therapeutics Inc.

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 436 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Industry: Biological Products, (No Diagnostic Substances) Peers: AMICUS THERAPEUTICS, INC. ARROWHEAD PHARMACEUTICALS, INC. Blueprint Medicines Corp ChemoCentryx, Inc. Denali Therapeutics Inc. Mirati Therapeutics, Inc. PTC THERAPEUTICS, INC. Ultragenyx Pharmaceutical Inc.